Financial Reports
Related Searches:
Filter by:
211 - 225 of 673 results
April 21, 2011
Gross business wins in the quarter were $329 million, representing a book to bill of 1.43.
Read More »
April 20, 2011
Tysabri revenues were up 23% to $245.2 million in the quarter, offsetting revenue loss from legacy products including Azactam, Prialt, Maxipime and Skelaxin, which contributed $38.7 million in 1Q10.
Read More »
April 20, 2011
Pharmaceutical sales were $3.8 billion in the quarter, up 12%. Humira sales were up 18% to $1.6 billion.
Read More »
April 19, 2011
Worldwide Pharmaceutical sales were $6.1 billion in the quarter.
Read More »
April 19, 2011
Pharmaceuticals sales were up 7% to $7.8 billion. Diovan sales were down 3% to $1.4 billion.
Read More »
April 18, 2011
Total revenue in the U.S. was $3.1 billion (+1%) primarily due to higher prices, partially offset by lower volume.
Read More »
April 14, 2011
Pharmaceuticals Division sales were down 2% in the quarter.
Read More »
March 22, 2011
Sales services segment revenue for the quarter was $41.4 million (+97%) and for the year was $133.3 million (+82%).
Read More »
March 10, 2011
Commercial manufacturing revenues were up 16% to $148.7 million
Read More »
March 9, 2011
Growth in the quarter was driven by Lab Services revenue (+16%) and a 59% increase in Manufacturing Services revenues.
Read More »
February 24, 2011
Operating income was $92 million for the year, representing 10.2% of revenue.
Read More »
February 16, 2011
During the quarter, the company ceased fill/finish operations at its Allston facility for products sold in the U.S.
Read More »
211 - 225 of 673 results
